Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 96, Issue 6, Pages 1695-1702Publisher
ENDOCRINE SOC
DOI: 10.1210/jc.2010-2822
Keywords
-
Categories
Funding
- Novo Nordisk
- Bristol-Myers Squibb
- GlaxoSmithKline
- Roche
- Sanofi-Aventis
- MerckCo.
- Daiichi Sankyo
- Pfizer
- Eli Lilly
- MannKind
- Takeda
- Forest
- Johnson Johnson
- Novartis
- Boehringer Ingelheim
- Amylin
- Merck
- Eli Lilly Co.
- Berlin-Chemie
- Merck Sharp Dohme
- MetaCure Inc.
- Menarini
Ask authors/readers for more resources
Context: Therapeutic proteins/peptides can produce immunogenic responses that may increase the risk of adverse events or reduce efficacy. Objective: The objectives were to measure and characterize antibody formation to liraglutide, a glucagon-like peptide-1 receptor agonist, to investigate the impact on glycemic control and safety, and to compare it with exenatide, an agent in the same class. Design: Antibody data were collected during six Liraglutide Effect and Action in Diabetes (LEAD) trials (26-104 wk duration). Setting: Samples for determination of antibody formation were collected at LEAD trial sites and analyzed at central laboratories. Participants: Antibodies were measured in LEAD trial participants with type 2 diabetes. Interventions: Interventions included once-daily liraglutide (1.2 or 1.8 mg) or twice-daily exenatide (10 mu g). Main Outcome Measures: The main outcome measures included the proportion of patients positive for anti-liraglutide or anti-exenatide antibodies, a glucagon-like peptide-1 cross-reacting effect, and an in vitro liraglutide- or exenatide-neutralizing effect. Change in glycosylated hemoglobin A(1c) (HbA(1c)) by antibody status and magnitude [negative, positive (high or low level)]. Results: After 26 wk, 32 of 369 (8.7%) and 49 of 587 (8.3%) patients had low-level antibodies to liraglutide 1.2 and 1.8 mg, respectively [mean 3.3% antibody-bound radioactivity out of total radioactivity (% B/T), range 1.6-10.7% B/T], which did not attenuate glycemic efficacy (HbA(1c) reductions 1.1-1.3% in antibody-positive vs. 1.2% in antibody-negative patients). In LEAD-6, 113 of 185 extension patients (61%) had anti-exenatide antibodies at wk 26 (range 2.4-60.2% B/T). High levels of antiexenatide antibodies were correlated with significantly smaller HbA(1c) reductions (P = 0.0022). After switching from exenatide to liraglutide, anti-exenatide antibodies did not compromise a further glycemic response to liraglutide (additional 0.4% HbA(1c) reduction). Conclusions: Liraglutide was less immunogenic than exenatide; the frequency and levels of anti-liraglutide antibodies were low and did not impact glycemic efficacy or safety. (J Clin Endocrinol Metab 96: 1695-1702, 2011)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available